Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824513 | 1.00 | NPSR1 (0.57) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| Isophthalic Acid SCHEMBL27777859 | 0.83 | KDR (0.62) | KDM4EKDRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL483375 | 0.80 | PDGFRB (0.60) | CYP1A2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL28007469 | 0.80 | NPSR1 (0.57) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| SCHEMBL11591503 | 0.80 | NPSR1 (0.57) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| SCHEMBL23055256 | 0.80 | NPSR1 (0.57) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| SCHEMBL11591505 | 0.80 | NPSR1 (0.57) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| SCHEMBL7033706 | 0.80 | NPSR1 (0.62) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| SCHEMBL2622213 | 0.79 | TRPV1 (0.54) | NPSR1KDM4ECYP1A2KDRRAB9A | |
| SCHEMBL12895711 | 0.79 | RAB9A (0.59) | NPSR1KDM4ECYP1A2KDRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-118221644-A | Pyrrolidine derivative, composition and application thereof | 上海京新生物医药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3246963-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| CN-114904527-B | Method for preparing N-monomethyl aromatic amine compound by catalyzing methanol | 华北电力大学 | 2023-05-26 | — | — | CN | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-114904527-A | Method for preparing N-monomethyl arylamine compound by catalyzing methanol | 华北电力大学 | 2022-08-16 | — | — | CN | disclosed |
| CN-114245794-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| CN-1582285-A | Heteroarylamine compounds useful as glycogen synthase kinase 3 beta inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-16 | — | — | CN | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-4396620-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382931-A | 3'-Substituted quinolinium cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | NPSR1 890/4885KDM4E 2624/4885CYP1A2 1377/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | NPSR1 2749/4885KDM4E 3621/4885CYP1A2 4661/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | NPSR1 180/4885KDM4E 3604/4885CYP1A2 905/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | NPSR1 821/4885KDM4E 3631/4885CYP1A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.